Prospective Assessment in Newborns for Diabetes Autoimmunity
NCT ID: NCT00649246
Last Updated: 2018-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
25055 participants
OBSERVATIONAL
1997-07-31
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes
NCT01846312
Development of Novel Biomarkers for the Early Diagnosis of Type 1 Diabetes
NCT04164966
Early Detection of Type 1 Diabetes
NCT06984185
Identification of β Cell Dysfunction in Relatives of Individuals With Type 1 Diabetes Mellitus
NCT04362917
Evaluating ImmuNe Changes in the Evolution of Pre Type 1 Diabetes With Adult ONset
NCT06006468
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
controls:
healthy individuals with no family history of type 1 diabetes
No interventions assigned to this group
2
high-risk:
Subjects with islet autoantibodies or high-risk diabetes genes
No interventions assigned to this group
3
type 1 diabetes:
subjects with type 1 diabetes
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
University of Florida
OTHER
Emory University
OTHER
Medical University of South Carolina
OTHER
University of South Carolina
OTHER
Augusta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jin-Xiong She
Director Center for Biotechnology and Genomic Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jin Xiong She, PhD
Role: PRINCIPAL_INVESTIGATOR
Augusta University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Florida
Gainesville, Florida, United States
Medical University of South Carolina
Charleston, South Carolina, United States
University of South Carolina
Columbia, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
PANDA web site
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DK63865 - PANDA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.